The research in the Movement Disorders Division is led by , the Chief of the Division. Dr. Khurana also leads the Precision Neurology Program at 91´óÉñ and Women’s Hospital, which includes an American Parkinson Disease Center for Advanced Research (APDA CAR). Current research efforts have a unified goal: to develop treatments for patients with degenerative movement disorders, including Parkinson’s disease, atypical Parkinsonian syndromes such as and , and .

Benefitting from expertise in biological profiling, biospecimen banking and stem-cell biology, we seek to develop approaches to establish precise treatment options tailored to specific patients.

Laboratory research in the Division occurs in the setting of Laboratories and a number of Translational and Basic Science Initiatives that bring us together with multiple partnering laboratories at 91´óÉñ and Women’s Hospital, Harvard Medical School and beyond:

We collaborate with academic laboratories within the Ann Romney Center for Neurologic Diseases focused on Parkinson’s disease and related disorders, and also with industry. These collaborations help move our vision forward toward executing clinical trials in stratified, well-defined patient population.

A centerpiece of our research efforts includes the Harvard Biomarker Study that is currently enrolling patients with neurodegenerative disorders and healthy controls.

Dr. Michael D. Fox in the Division leads the cross-department that develops new treatments for patients with brain disease by directly targeting brain networks responsible for neurological and psychiatric symptoms.

Translational and Basic Science Initiatives - collaborative efforts centered specifically on Movement Disorders